<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2905222082
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CRESCHOL 20 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        103.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Creschol&reg;</strong> belongs to a group of medicines called statins.<br />You have been prescribed Creschol&reg; because:<br />&bull;You have a high cholesterol level. This means you are at risk from a heart attack or stroke. Creschol&reg; is used in adults, adolescents and children 6 years or older to treat high cholesterol.<br />&bull;You have been advised to take a statin, because changing your diet and doing more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking Creschol&reg;.<br />&bull;You have other factors that increase your risk of having a heart attack, stroke or related health problems.<br />Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to build up of fatty deposits in your arteries.<br />Why is it important to keep taking Creschol&reg;?<br />Creschol&reg; is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.<br />There are different types of cholesterol found in the blood-&lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).<br />&bull;Creschol&reg; can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.<br />&bull;It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.<br />For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow. Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems. You need to keep taking Creschol&reg;, even if it has got your cholesterol to the right level, because it prevents your cholesterol levels from creeping up again and causing build up of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take <strong>Creschol&reg;</strong><br />&bull;If you have ever had an allergic reaction to <strong>Creschol&reg;</strong>, or to any of its ingredients.<br />&bull;If you are pregnant or breast-feeding. If you become pregnant while taking <strong>Creschol&reg;</strong> stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking <strong>Creschol&reg;</strong> by using suitable contraception.<br />&bull;If you have liver disease.<br />&bull;If you have severe kidney problems.<br />&bull;If you have repeated or unexplained muscle aches or pains.<br />&bull;If you take a drug combination of sofosbuvir/velpatasvir/voxilaprevir (used for viral infection of the liver called hepatitis C).<br />&bull;If you take a drug called ciclosporin (used, for example, after organ transplants).<br />If any of the above applies to you (or you are in doubt), please go back and see your doctor.<br />In addition, do not take rosuvastatin 40 mg (the highest dose):<br />&bull;If you have moderate kidney problems (if in doubt, please ask your doctor).<br />&bull;If your thyroid gland is not working properly.<br />&bull;If you have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.<br />&bull;If you regularly drink large amounts of alcohol.<br />&bull;If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).<br />&bull;If you take other medicines called fibrates to lower your cholesterol.<br />If any of the above applies to you (or you are in doubt), please go back and see your doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Creschol&reg;:<br />&bull;If you have problems with your kidneys.<br />&bull;If you have problems with your liver.<br />&bull;If you have had repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.<br />&bull;If you regularly drink large amounts of alcohol.<br />&bull;If your thyroid gland is not working properly.<br />&bull;If you take other medicines called fibrates to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before.<br />&bull;If you take medicines used to treat the HIV infection e.g. ritonavir with lopinavir and/or atazanavir.<br />&bull;If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection), orally or by injection. The combination of fusidic acid and Creschol&reg; can lead to serious muscle problems (rhabdomyolysis).<br />&bull;If you are over 70 (as your doctor needs to choose the right start dose of Creschol&reg; to suit you).<br />&bull;If you have severe respiratory failure.<br />&bull;If you are of Asian origin that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of Creschol&reg; to suit you.<br />If any of the above applies to you (or if you are not sure):<br />Do not take rosuvastatin 40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of Creschol&reg;.<br />In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with Creschol&reg;.<br />While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.<br />Children and adolescents<br />&bull;If the patient is under 6 years old: Creschol&reg; should not be given to children younger than 6 years.<br />&bull;If the patient is below 18 years of age: The rosuvastatin 40 mg tablet is not suitable for use in children and adolescents below 18 years of age.<br />Taking other medicines<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor if you are taking any of the following:<br />&bull;Ciclosporin (used for example, after organ transplants).<br />&bull;Warfarin or clopidogril (or any other drug used for thinning the blood).<br />&bull;Fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe).<br />&bull;Indigestion remedies (used to neutralise acid in your stomach).<br />&bull;erythromycin (an antibiotic), fusidic acid (an antibiotic).<br />&bull;An oral contraceptive (the pill).<br />&bull;Regorafenib (used to treat cancer).<br />&bull;Darolutamide (used to treat cancer).<br />&bull;Hormone replacement therapy.<br />&bull;Any of the following drugs used to treat viral infections, including HIV or hepatitis C infection, alone or in combination (please see Warnings and precautions): ritonavir, lopinavir, atazanavir, sofosbuvir, voxilaprevir, ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir, elbasvir, glecaprevir, pibrentasvir.<br />The effects of these medicines could be changed by Creschol&reg; or they could change the effects of Creschol&reg;.<br />If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart Creschol&reg;. Taking Creschol&reg; with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis).<br />Taking Creschol&reg; with food and drink<br />You can take Creschol&reg; with or without food.<br />Pregnancy and breast-feeding<br />Do not take Creschol&reg; if you are pregnant or breast-feeding. If you become pregnant while taking Creschol&reg; stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking Creschol&reg; by using suitable contraception. Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />Most people can drive a car and operate machinery while using Creschol&reg;, it will not affect their ability. However, some people feel dizzy during treatment with Creschol&reg;. If you feel dizzy, consult your doctor before attempting to drive or use machines.<br />Important information about some of the ingredients of Creschol&reg;<br />Creschol&reg; contains lactose<br />If you have been told by your doctor that you have an intolerance to some sugars (lactose or milk sugar), contact your doctor before taking Creschol&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Creschol&reg; as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Usual doses in adults<br />If you are taking Creschol&reg; for high cholesterol:<br />Starting dose<br />Your treatment with Creschol&reg; must start with the 5 mg or the 10 mg dose, even if you have taken a higher dose of a different statin before.<br />The choice of your start dose will depend upon:<br />&bull;Your cholesterol level.<br />&bull;The level of risk you have of experiencing a heart attack or stroke.</p><p>&bull;Whether you have a factor that may make you more sensitive to possible side effects.<br />Please check with your doctor or pharmacist which start dose of Creschol&reg; will best suit you.<br />Your doctor may decide to give you the lowest dose (5 mg) if:<br />&bull;You are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).<br />&bull;You are over 70 years of age.<br />&bull;You have moderate kidney problems.<br />&bull;You are at risk of muscle aches and pains (myopathy).<br />Increasing the dose and maximum daily dose<br />Your doctor may decide to increase your dose. This is so that you are taking the amount of Creschol&reg; that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then 20 mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.<br />The maximum daily dose of rosuvastatin is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.<br />If you are taking Creschol&reg; to reduce your risk of having a heart attack, stroke or related health problems: The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.<br />Use in children and adolescents aged 6-17 years<br />The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start dose is 5 mg per day, and your doctor may gradually increase your dose to find the right amount of Creschol&reg; for you. The maximum daily dose of Creschol&reg; is 10 or 20 mg for children aged 6 to 17 years depending on your underlying condition being treated. Take your dose once a day. Rosuvastatin 40 mg tablet should not be used by children.<br />Taking your tablets<br />Swallow each tablet whole with a drink of water.<br />Take Creschol&reg; once daily. You can take it at any time of the day with or without food. Try to take your tablet at the same time every day to help you to remember it.<br />Regular cholesterol checks: It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level. Your doctor may decide to increase your dose so that you are taking the amount of Creschol&reg; that is right for you.<br />If you take more Creschol&reg; than you should<br />Contact your doctor or nearest hospital for advice. If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking Creschol&reg;.<br />If you forget to take Creschol&reg;<br />Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Creschol&reg;<br />Talk to your doctor if you want to stop taking Creschol&reg;. Your cholesterol levels might increase again if you stop taking Creschol&reg;.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Creschol&reg; </strong>can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be.<br />They are usually mild and disappear after a short time.<br />Stop taking Creschol&reg; and seek medical help immediately if you have any of the following allergic reactions:<br />&bull;Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat.<br />&bull;Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing.<br />&bull;Severe itching of the skin (with raised lumps).<br />Also, stop taking Creschol&reg; and talk to your doctor immediately:<br />&bull;If you have any unusual aches or pains in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as rhabdomyolysis.<br />&bull;If you experience muscle rupture.<br />&bull;If you have lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).<br />Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients):<br />&bull;Headache, stomach pain, constipation, feeling sick, muscle pain, feeling weak, dizziness.<br />&bull;An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your Creschol&reg; tablets (only rosuvastatin 40 mg).<br />&bull;Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.<br />Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients):<br />&bull;Rash, itching or other skin reactions.<br />&bull;An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your Creschol&reg; tablets (only Creschol&reg; 5 mg, 10 mg and 20 mg).<br />Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients):<br />&bull;Severe allergic reaction, signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps).<br />If you think you are having an allergic reaction, then stop taking Creschol&reg; and seek medical help immediately.<br />&bull;Muscle damage in adults, as a precaution, stop taking Creschol&reg; and talk to your doctor immediately if you have any unusual aches or pains in your muscles which go on for longer than expected.<br />&bull;A severe stomach pain (inflamed pancreas).<br />&bull;Increase in liver enzymes in the blood.<br />&bull;Bleeding or bruising more easily than normal due to low level of blood platelets.<br />&bull;Lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).<br />Very rare possible side effects (these may affect less than 1 in 10,000 patients):<br />&bull;Jaundice (yellowing of the skin and eyes), hepatitis (an inflamed liver), traces of blood in your urine, damage to the nerves of your legs and arms (such as numbness), joint pain, memory loss and breast enlargement in men (gynaecomastia).<br />Side effects of unknown frequency may include:<br />&bull;Diarrhea (loose stools), Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals), cough, shortness of breath, oedema (swelling), sleep disturbances, including insomnia and nightmares, sexual difficulties, depression, breathing problems, including persistent cough and/or shortness of breath or fever, tendon injury and muscle weakness that is constant.<br />If you get any side effects talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use <strong>Creschol&reg;</strong> tablets after the expiry date (EXP) which is stated on the blister and the carton.<br />The expiry date refers to the last day of that month.<br /><strong>Creschol&reg;</strong> tablets: Store below 30&deg;C.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What <strong>Creschol&reg; </strong>tablets contain<br />The active substance is Rosuvastatin (as Rosuvastatin Calcium).<br />The other ingredients are Calcium phosphate, microcrystalline cellulose, lactose Monohydrate, crospovidone, magnesium stearate, HPMC, PEG, titanium dioxide, ferric oxide red and ferric oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Creschol® 5mg: Pale Yellow, round biconvex film coated tablets engraved with H51 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use.
Creschol® 10mg: Light pink, round biconvex film-coated tablets engraved with H53 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use.
Creschol® 20mg: Light pink, round biconvex film-coated tablets engraved with H55 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use.
Pack size: 30 Film Coated Tablets (10 tablets/blister, 3 blisters/Pack).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Med City Pharma-KSA.</p><p>1st Industrial city, Phase 5, Jeddah &ndash;KSA.</p><p>Tel: 00966920003288</p><p>Mobile: 00966555786968</p><p>P.O .Box: 4072 - Jeddah 22429</p><p>E-mail: info@medcitypharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي كريسكول إلى مجموعة من الأدوية تعرف بالستاتين.&nbsp;</p><p>لقد تم وصف <strong>كريسكول</strong> لك بسبب:</p><p style="margin-right:40px">&bull;أنك تعاني من ارتفاع مستوى الكوليستيرول في الدم. هذا يعني أنك معرض لخطر الإصابة بنوبة قلبية أو سكتة دماغية. يستعمل كريسكول للبالغين، المراهقين و الأطفال الذين تبلغ أعمارهم 6 سنوات أو أكثر &nbsp;لعلاج إرتفاع مستوى الكوليسترول.</p><p style="margin-right:40px">.لقد تم إعطاؤك هذا الدواء من مجموعة الستاتين، لأن تغيير نظامك الغذائي والقيام بمزيد من التمارين &nbsp;الرياضية لم يعد كافياً لتصحيح مستويات الكوليستيرول. يجب عليك الاستمرار باتباع نظام غذائي قليل .الكوليستيرول وممارسة التمارين الرياضية أثناء فترة تناول كريسكول</p><p style="margin-right:40px">.أنك تعاني من عوامل أخرى تزيد من خطر الإصابة بنوبة قلبية، سكتة دماغية أو أي مشاكل صحية &bull;تتعلق بذلك.</p><p style="margin-right:40px">النوبة القلبية، السكتة الدماغية و المشاكل الأخرى قد تنتج عن الإصابة بمرض يعرف بتصلب الشرايين. تصلب الشرايين ناتج عن تراكم ترسبات الدهون في الشرايين .</p><p style="margin-right:40px"><strong>لماذا من الضروري الاستمرار في تناول كريسكول؟</strong></p><p style="margin-right:40px">يستعمل&nbsp;<strong>كريسكول</strong>&nbsp;لتصحيح مستويات المواد الدهنية في الدم و تعرف بالدهون، الأكثر شيوعاً منها هو &nbsp;الكوليستيرول.</p><p style="margin-right:40px">&nbsp;يوجد أنواع مختلفة من الكوليستيرول في الدم - الكوليسترول&nbsp;&raquo;الضار&laquo;&nbsp;(ليبوبروتين منخفض الكثافة) و&nbsp; الكوليستيرول &raquo; الجيد &laquo;&nbsp; (ليبوبروتين عالي الكثافة).</p><p style="margin-right:40px">.&nbsp;يعمل <strong>كريسكول&nbsp;</strong>على تخفيض مستوى الكوليستيرول&nbsp; &raquo;الضار&laquo;&nbsp;و زيادة مستوى الكوليستيرول&nbsp;&raquo; الجيد &laquo;.<br />.يعمل <strong>كريسكول</strong> عن طريق المساعدة في حصر إنتاج الجسم للكوليستيرول&nbsp; .&raquo;الضار&laquo;&nbsp;و يحسن أيضاً قدرة&nbsp;الجسم على التخلص منه من الدم.</p><p style="margin-right:40px">عند معظم الأشخاص، لا يؤدي ارتفاع مستوى الكوليستيرول إلى ظهور أي أعراض من الممكن أن يشعر بها المريض. و مع ذلك، إذا لم يعالج، قد تتراكم الترسبات الدهنية في جدار الأوعية الدموية مما يسبب تضيقها. في بعض الأحيان، قد يحدث انسداد في هذه الأوعية الدموية المتضيقة و الذي يمكن أن يوقف تدفق الدم إلى القلب أو الدماغ مما يؤدي إلى الإصابة بالنوبة القلبية أو السكتة الدماغية. عن طريق تخفيض مستويات الكوليستيرول، قد يقل خطر الإصابة بالنوبة القلبية، أو السكتة الدماغية أو أي مشاكل صحية تتعلق بذلك. قد&nbsp;تحتاج للاستمرار في تناول <strong>كريسكول</strong> حتى لو أصبح مستوى الكوليستيرول طبيعياً، حيث أنه يمنع ارتفاع ،&nbsp;مستويات الكوليستيرول مرة أخرى و تراكم الترسبات الدهنية. و مع ذلك، يجب التوقف عن تناوله إذا أخبرك طبيبك بذلك، أو عند حصول الحمل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استعمال كريسكول&reg;</strong><br />إذا سبق و عانيت من تفاعل تحسسي ل<strong>كريسكول&reg;,&nbsp;</strong>أو لأي مكونات أخرى في هذا الدواء.<strong>&nbsp;</strong><br />إذا كنت حامل أو مرضعة. إذا حصل الحمل أثناء فترة تناول <strong>كريسكول&reg;</strong> توقفي عن تناوله فوراً و أخبري طبيبك. يجب على النساء تجنب حصول الحمل أثناء فترة تناول كريسكول عن طريق استعمال وسيلة مناسبة لمنع الحمل.</p><p>&nbsp;.إذا كنت تعاني من مرض في الكبد.</p><p>&bull;إذا كنت تعاني من مشاكل حادة في الكلى.</p><p>&bull;إذا كنت تعاني من آلام مستمرة، متكررة أو غير مبررة في العضلات.</p><p>&bull;إذا كنت تتناول دواء مركب من سوفوسبوفير/فيلباتاسفير/فوكسيلابرفير يستعمل لعلاج التهاب فيروسي في (الكبد يعرف بالتهاب الكبد ج).</p><p>,إذا كنت تتناول دواء يسمى سايكلوسبورين (يستعمل، على سبيل المثال، بعد زرع الأعضاء) .</p><p>إذا كان أي مما ذكر في الأعلى ينطبق عليك أو كان لديك شك، قم بمراجعة الطبيب و استشارته.</p><p>بالإضافة إلى ذلك، لا تتناول روسوڤاستاتين 40 ملغم (أعلى جرعة):</p><p>إذا كنت تعاني من مشاكل متوسطة في الكلى إذا كان لديك شك، الرجاء أن تسأل طبيبك .&bull;()إذا كانت الغدة الدرقية لا تعمل بشكل جيد.&bull;إذا كنت تعاني من آلام مستمرة، متكررة أو غير مبررة في العضلات. أو سبق و عانيت أنت أو أفراد &bull; عائلتك من الإصابة بمشاكل العضلات، أو عانيت في السابق من مشاكل العضلات عند تناول أدوية أخرى مخفضة للكوليستيرول.إذا كنت تتناول باستمرار كميات كبيرة من الكحول.&bull;إذا كنت من أصول آسيوية يابانية، صينية، فلبينية، فيتنامية، كورية و هندية .&bull;()إذا كنت تتناول أدوية أخرى تعرف بفايبريت لتخفيض مستويات الكوليستيرول.&bull;إذا كان أي مما ذكر في الأعلى ينطبق عليك أو إذا كان لديك شك، قم بمراجعة الطبيب و استشارته.()الاحتياطات و المحاذير:&reg;أخبر طبيبك أو الصيدلي قبل القيام بتناول كريسكولإذا كنت تعاني من مشاكل في الكلى.&bull;إذا كنت تعاني من مشاكل في الكبد.&bull;إذا كنت تعاني من آلام مستمرة، متكررة أو غير مبررة في العضلات, أو سبق و عانيت أنت أو أفراد &bull; عائلتك من الإصابة بمشاكل العضلات، أو عانيت في السابق من مشاكل العضلات عند تناول أدوية أخرى مخفضة للكوليستيرول. أخبر طبيبك فوراً إذا كنت تعاني من آلام مستمرة، غير مبررة في العضلات خاصة إذا كنت تشعر بالمرض أو كنت تعاني من حمى. أيضاً أخبر طبيبك أو الصيدلي إذا كنت تعاني من ضعف دائم في العضلات.إذا كنت تتناول باستمرار كميات كبيرة من الكحول.&bull;إذا كانت الغدة الدرقية لا تعمل بشكل جيد.&bull;إذا كنت تتناول أدوية أخرى تسمى فايبريت لتخفيض مستوى الكوليستيرول. الرجاء قراءة هذه النشرة جيداً، &bull; حتى و إن كنت قد تناولت في السابق أدوية أخرى لعلاج ارتفاع مستويات الكوليستيرول. إذا كنت تتناول أدوية تستعمل لعلاج التهاب نقص المناعة المكتسبة مثل ريتوناڤير مع لوبيناڤير، و/أو &bull;أتازاناڤير.إذا كنت تتناول أو تناولت دواء يعرف بحمض الفيوسيديك خلال السبعة أيام السابقة دواء يستعمل لعلاج &bull;)في الوقت ( &reg;الإلتهابات البكتيرية، عن طريق الفم او عن طريق الحقن. استعمال حمض الفيوسيديك و كريسكول ذاته قد يؤدي إلى مشاكل عضلية خطيرة تحلل العضلة المخططة. )إذا كان عمرك يزيد عن 70 سنة حيث أن طبيبك يحتاج إلى اختيار الجرعة الابتدائية المناسبة من &bull;)).&reg;كريسكولإذا كنت تعاني من قصور تنفسي حاد. &bull;إذا كنت من أصول آسيوية - يابانية، صينية، فلبينية، فيتنامية، كورية و هندية. سيحتاج طبيبك إلى اختيار &bull;.&reg;الجرعة الابتدائية المناسبة من كريسكولإذا كان أي مما ذكر في الأعلى ينطبق عليك أو إذا لم تكن متأكداً:() لا تتناول روسوڤاستاتين 40 ملغم أعلى جرعة و قم باستشارة طبيبك أو الصيدلي قبل البدء بتناول أي ().&reg;جرعة من كريسكول عند عدد قليل من الأشخاص، قد تؤثر الأدوية من مجموعة الستاتين على الكبد. هذا يتم معرفته عن طريق فحص بسيط يُظهر زيادة مستويات إنزيمات الكبد في الدم. لهذا السبب، سيقوم طبيبك عادة بطلب إجراء () .&reg; فحص للدم فحص وظيفة الكبد قبل وأثناء فترة العلاج بكريسكول أثناء تناولك هذا الدواء سيقوم طبيبك بمراقبتك جيداً إذا كنت مصاباً بداء السكري أو معرض لخطر الإصابة بداء السكري. من المحتمل أن تتعرض لخطر الإصابة بداء السكري، إذا كنت تعاني من ارتفاع مستويات السكر والدهون في الدم، زيادة في الوزن و ارتفاع ضغط الدم.الأطفال و المراهقونللأطفال الأصغر من 6 سنوات.&bull; &reg;<br />المرضى الذين تقل أعمارهم عن 6 سنوات: يجب عدم إعطاء كريسكولالمرضى الذين تقل أعمارهم عن 18 سنة: أقراص روسوڤاستاتين 40 ملغم غير مناسبة للأطفال و المراهقين &bull;الأقل من 18 سنةتناول أدوية أخرى أخبر الطبيب أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية:سايكلوسبورين يستعمل على سبيل المثال، بعد زرع الأعضاء . &bull;()وارفارين أو كلوبيدوجريل أو أي دواء آخر يستعمل للوقاية من تجلط الدم .&bull;()فايبريت مثل جيمفيبروزيل، فينوفايبريت أو أي دواء آخر يستعمل لتقليل مستوى الكوليستيرول مثل &bull;())ايزيتيمايب.(أدوية عسر الهضم يستعمل لمعادلة الحمض في المعدة .&bull;()اريثرومايسين مضاد حيوي ، حمض الفيوسيديك مضاد حيوي . &bull;(())موانع الحمل التي يتم تناولها عن طريق الفم قرص . &bull;()ريجورافينيب يستعمل لعلاج السرطان .&bull;()داروليوتاميد يستعمل لعلاج السرطان .&bull;()العلاج البديل للهرمونات. &bull;أي من الأدوية التالية التي تستعمل لعلاج الالتهابات الفيروسية، بما في ذلك نقص المناعة المكتسبة أو &bull; التهاب الكبد ج، بشكل منفرد أو بشكل متزامن: ريتونافير، لوبينافير، أتازانافير، سوفوسبوفير، فوكسيلابريفير، أومبيتاسفير، باريتابريفير، داسابيوفير، فيلباتاسفير، جرازوبريفير، إلباسفير، جليسابريفير، بيبرينتاسفير. .&reg;أو قد تؤثر على مفعول كريسكول &reg;قد يتغير مفعول هذه الأدوية بتناول كريسكول إذا كنت تحتاج لتناول حمض الفيوسيديك عن طريق الفم لعلاج التهاب بكتيري، ستحتاج إلى إيقاف استعمال مع &reg;مرة أخرى. تناول كريسكول &reg;هذا الدواء بشكل مؤقت. سيخبرك الطبيب متى تستطيع إستعمال كريسكولحمض الفيوسيديك نادراً ما يؤدي إلى ضعف العضلات، تألم عند اللمس أو ألم تحلل العضلة المخططة.()مع الطعام و الشراب &reg;تناول كريسكولمع أو بدون تناول الطعام. &reg;يمكنك تناول كريسكولالحمل و الإرضاع توقفي عن &reg;إذا كنت حامل أو مرضعة. إذا حصل الحمل أثناء فترة تناول كريسكول &reg;يجب عدم تناول كريسكول عن طريق &reg;تناوله فوراً و أخبري طبيبك. يجب على النساء تجنب حصول الحمل أثناء فترة تناول كريسكولاستعمال وسيلة مناسبة لمنع الحمل. استشيري طبيبك أو الصيدلي قبل تناول أي دواء.قيادة المركبات و استخدام الآلات لا يؤثر على قدرتهم. ،&reg;يستطيع معظم الأشخاص قيادة المركبة و تشغيل الآلات أثناء فترة استعمال كريسكول إذا شعرت بالدوار، استشر طبيبك قبل .&reg;مع ذلك، يشعر بعض الأشخاص بالدوار أثناء فترة العلاج بكريسكولمحاولة القيادة أو استخدام الآلات.&reg;معلومات مهمة حول بعض مكونات كريسكول على لاكتوز &reg;يحتوي كريسكول إذا أخبرت من قبل الطبيب بأنك لا تستطيع تحمل بعض أنواع السكريات لاكتوز أو سكر الحليب، استشر ().&reg;طبيبك قبل تناول كريسكول</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> كما أخبرك الطبيب. يجب أن تتأكد من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الجرعات</strong><strong> </strong><strong>الاعتيادية</strong><strong> </strong><strong>للبالغين</strong></p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>مستوى</strong><strong> </strong><strong>الكوليستيرول</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الابتدائية</strong></p><p dir="RTL">يجب أن يبدأ العلاج <strong>بكريسكول</strong><strong><sup>&reg;</sup></strong> بجرعة 5 ملغم أو 10 ملغم، حتى و إن تناولت سابقاً جرعة أعلى من أدوية أخرى من مجموعة الستاتين.</p><p dir="RTL"><strong>اختيار</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>الابتدائية</strong><strong> </strong><strong>يعتمد</strong><strong> </strong><strong>على</strong><strong>:</strong></p><p dir="RTL">مستوى الكوليستيرول.</p><p dir="RTL">احتمالية الإصابة بنوبة قلبية أو سكتة دماغية.</p><p dir="RTL">إذا كان لديك عامل يجعلك أكثر حساسية للآثار الجانبية المحتملة.</p><p dir="RTL">اسأل طبيبك أو الصيدلي عن الجرعة الابتدائية المناسبة لك من <strong>كريسكول</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>يقرر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إعطائك</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>جرعة</strong><strong> (5 </strong><strong>ملغم</strong><strong>):</strong></p><p dir="RTL">إذا كنت من أصول آسيوية (يابانية، صينية، فلبينية، فيتنامية، كورية و هندية).</p><p dir="RTL">إذا كان عمرك يزيد عن 70 سنة.</p><p dir="RTL">إذا كنت تعاني من مشاكل متوسطة في الكلى.</p><p dir="RTL">إذا كنت معرض لخطر الإصابة&nbsp; بآلام مستمرة في العضلات (اعتلال عضلي).</p><p dir="RTL"><strong>زيادة</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>اليومية</strong><strong> </strong><strong>القصوى</strong><strong>: </strong></p><p dir="RTL">قد يقرر طبيبك زيادة الجرعة بحيث تصل إلى جرعة <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> المناسبة لك. إذا بدأت بجرعة 5 ملغم.</p><p dir="RTL">قد يقرر طبيبك مضاعفة الجرعة إلى 10 ملغم، ثم إلى 20 ملغم و من ثم إلى 40 ملغم إذا احتجت&nbsp; لذلك. إذا بدأت بجرعة 10 ملغم، قد يقرر طبيبك مضاعفة الجرعة إلى 20 ملغم و بعد ذلك 40 ملغم إذا احتجت لذلك. سيكون هناك فترة أربعة أسابيع بين تعديل كل جرعة والأخرى.</p><p dir="RTL">الجرعة اليومية القصوى من روسوڤاستاتين هي 40 ملغم. هذه الجرعة فقط للمرضى الذين يعانون من ارتفاع مستويات الكوليستيرول و ارتفاع خطر الإصابة بالنوبات القلبية أو السكتة الدماغية.</p><p dir="RTL">الذين لم يتم خفض مستويات الكوليستيرول لديهم بشكل كافٍ عند استعمال <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> 20 ملغم.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>لتقليل</strong><strong> </strong><strong>خطر</strong><strong> </strong><strong>الإصابة</strong><strong> </strong><strong>بالنوبة</strong><strong> </strong><strong>القلبية،</strong><strong> </strong><strong>السكتة</strong><strong> </strong><strong>الدماغية</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>مشاكل</strong><strong> </strong><strong>صحية</strong><strong> </strong><strong>تتعلق</strong><strong> </strong><strong>بذلك</strong><strong>:</strong></p><p dir="RTL">الجرعة اليومية الموصى بها هي 20 ملغم. مع ذلك، قد يقرر طبيبك استعمال جرعة أقل من ذلك إذا كنت تعاني من أي من العوامل التي ذكرت في الأعلى.</p><p dir="RTL"><strong>استعماله</strong><strong> </strong><strong>للأطفال</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المراهقين</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>تتراوح</strong><strong> </strong><strong>أعمارهم</strong><strong> </strong><strong>بين</strong><strong> 6 - 17 </strong><strong>سنة</strong></p><p dir="RTL">تتراوح الجرعة للأطفال و المراهقين الذين يبلغون من العمر6 - 17 سنة ما بين 5 - 20 ملغم مرة واحدة يومياً. الجرعة الابتدائية الاعتيادية هي 5 ملغم. قد يزيد طبيبك الجرعة تدريجياً للحصول على كمية مناسبة من <strong>كريسكول</strong><strong><sup>&reg;</sup></strong>. الجرعة اليومية القصوى من <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> هي 10 أو 20 ملغم للأطفال الذين يبلغون من العمر 6 - 17 سنة اعتماداً على الحالة المراد علاجها. تناول الجرعة مرة واحدة يومياً. يجب عدم تناول قرص روسوڤاستاتين 40 ملغم من قبل الأطفال.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>الأقراص</strong></p><p dir="RTL">قم ببلع القرص كاملاً مع شرب كمية من الماء.</p><p dir="RTL">تناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> مرة واحدة يومياً. يمكن تناوله في أي وقت من اليوم مع أو بدون تناول الطعام. حاول أن تتناول القرص في نفس الوقت من كل يوم ليساعدك ذلك على تذكر تناوله.</p><p dir="RTL"><strong>فحوصات</strong><strong> </strong><strong>منتظمة</strong><strong> </strong><strong>لمراقبة</strong><strong> </strong><strong>مستوى</strong><strong> </strong><strong>الكوليستيرول</strong></p><p dir="RTL">من الضروري مراجعة الطبيب لإجراء فحوصات الكوليستيرول بانتظام، لتتأكد من وصول مستوى الكوليستيرول إلى المستوى الطبيعي و بقائه كذلك. قد يقرر طبيبك زيادة الجرعة، و في هذه الحالة تكون أنت تتناول جرعة مناسبة من <strong>كريسكول</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">قم بالاتصال بطبيبك أو بأقرب مستشفى لطلب المساعدة. إذا ذهبت إلى المستشفى أو تلقيت علاجاً لحالة أخرى، أخبر الطاقم&nbsp; الطبي بأنك تتناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">لا تقلق، فقط تناول الجرعة التالية كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">استشر طبيبك إذا كنت تريد التوقف عن تناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong>. قد ترتفع مستويات الكوليستيرول مرة أخرى إذا توقفت عن تناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> آثاراً جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">من الضروري معرفة طبيعة هذه الآثار الجانبية. عادة تكون معتدلة وتختفي بعد فترة قصيرة.</p><p dir="RTL"><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>و</strong><strong> </strong><strong>اطلب</strong><strong> </strong><strong>مساعدة</strong><strong> </strong><strong>طبية</strong><strong> </strong><strong>فوراً</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>التفاعلات</strong><strong> </strong><strong>التحسسية</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">صعوبة في التنفس، مع أو بدون تورم الوجه، الشفاه، اللسان و/أو الحلق.</p><p dir="RTL">تورم الوجه، الشفاه، اللسان، و/أو الحلق و الذي قد يسبب صعوبة في البلع.</p><p dir="RTL">حكة حادة في الجلد (مع بروز كتل على سطح الجلد).</p><p dir="RTL">بقع حمراء غير مرتفعة، تشبه النقاط أو بقع دائرية على الجذع، غالبا مع تنفطات في المركز، تقشر الجلد، تقرحات في الفم، الحلق، الأنف، الأعضاء التناسلية و العيون. يمكن أن يسبق هذا الطفح الجلدي الخطير حمى و أعراض تشبه الإنفلونزا (متلازمة ستيڤن جونسون).</p><p dir="RTL">طفح جلدي منتشر، ارتفاع درجة حرارة الجسم، تضخم الغدد الليمفاوية (طفح جلدي ناتج عن استعمال بعض الأدوية يرافقه ظهور كثرة الحمضات و أعراض جهازية أو متلازمة فرط الحساسية الدوائية).</p><p dir="RTL"><strong>أيضاً،</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>و</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فوراً</strong><strong>:</strong></p><p dir="RTL">إذا حصل لديك أي آلام مستمرة، متكررة أو غير مبررة في العضلات و التي تستمر لفترة أطول مما هو متوقع. الأعراض العضلية شائعة أكثر عند الأطفال و المراهقين منه عند البالغين. كما هو الحال مع الأدوية الأخرى من مجموعة الستاتين، عدد قليل جداً من الأشخاص حصل لديهم آثار جانبية غير مرغوب فيها في العضلات و نادراً ما تتطور لتسبب تلف للعضلات مهدد للحياة يعرف بتحلل العضلة المخططة.</p><p dir="RTL">إذا عانيت من تمزق في العضلات.</p><p dir="RTL">إذا عانيت من متلازمة مرض يشبه الحمامي (بما في ذلك طفح، اضطرابات المفاصل و تأثيرات على خلايا الدم).</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>بين</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>و</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>مريض</strong><strong>):</strong></p><p dir="RTL">صداع، ألم المعدة، إمساك، شعور بالغثيا، ألم عضلات، شعور بالضعف، شعور بالدوار.</p><p dir="RTL">زيادة في كمية البروتين في البول، عادة تعود إلى وضعها الطبيعي من تلقاء نفسها دون الحاجة إلى التوقف عن تناول أقراص <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> (فقط روسوڤاستاتين 40 ملغم).</p><p dir="RTL">داء السكري. هذا متوقع أكثر إذا كنت تعاني من ارتفاع مستويات السكر و الدهون في الدم، زيادة في الوزن و ارتفاع ضغط الدم. سيراقبك الطبيب أثناء تناول هذا الدواء.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>بين</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>و</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>مريض</strong><strong>):</strong></p><p dir="RTL">طفح، حكة أو تفاعلات جلدية أخرى.</p><p dir="RTL">زيادة في كمية البروتين في البول، عادة تعود إلى وضعها الطبيعي من تلقاء نفسها دون الحاجة إلى التوقف عن تناول أقراص <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> (فقط <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> 5 ملغم، 10 ملغم و 20 ملغم).</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>بين</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>و</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>مريض</strong><strong>):</strong></p><p dir="RTL">تفاعل تحسسي حاد، تتضمن العلامات تورم الوجه، الشفاه، اللسان و/أو الحلق، صعوبة في البلع و التنفس، حكة حادة في الجلد (مع بروز كتل على سطح الجلد). إذا كنت تعتقد بأن لديك تفاعل تحسسي، توقف عن تناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong><sup> </sup>و اطلب مساعدة طبية فوراً.</p><p dir="RTL">تلف العضلات عند البالغين، كإجراء احتياطي، توقف عن تناول <strong>كريسكول</strong><strong><sup>&reg;</sup></strong> و قم باستشارة طبيبك فوراً إذا كان لديك آلام مستمرة، متكررة أو غير مبررة في العضلات و التي تستمر لفترة أطول مما هو متوقع.</p><p dir="RTL">ألم حاد في المعدة (التهاب البنكرياس).</p><p dir="RTL">زيادة إنزيمات الكبد في الدم.</p><p dir="RTL">حدوث نزيف أو ظهور كدمات بشكل أكثر من الوضع الطبيعي بسبب نقص صفيحات الدم.</p><p dir="RTL">متلازمة مرض يشبه الحمامى (بما في ذلك طفح، اضطرابات المفاصل و تأثيرات على خلايا الدم).</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>نادرة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>مريض</strong><strong>):</strong></p><p dir="RTL">يرقان (اصفرار الجلد و المنطقة البيضاء في العيون)، التهاب الكبد، آثار دماء في البول، تلف أعصاب الساقين و الذراعين (مثل التنمل)، ألم المفصل، فقدان الذاكرة، تضخم الثدي عند الرجال.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>تكرارها</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>معروف</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تتضمن</strong><strong>:</strong></p><p dir="RTL">إسهال (إسهال رخو).</p><p dir="RTL">متلازمة ستيڤن-جونسون (حالة خطيرة تتكون فيها نفطات على الجلد، الفم، العيون، والأعضاء التناسلية، سعال، قصر النفس، أوديما (تورم)، اضطرابات النوم، تتضمن أرق وكوابيس، عجز جنسي، اكتئاب، مشاكل في التنفس، تتضمن سعال دائم و/أو قصر النفس أو حمى، إصابة في الوتر، ضعف دائم في العضلات.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>. </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط، الملصق و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>كريسكول</strong><strong><sup>&reg;</sup></strong> أقراص: يحفظ في درجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي روسوڤاستاتين (روسوڤاستاتين كالسيوم).</p><p dir="RTL">المكونات الأخرى هي كالسيوم فوسفات ثلاثي القاعدة غير مائي، ميكروكريستالين سلليلوز، لاكتوز مونوهيدرات، رذاذ لاكتوز مونوهيدرات المجفف، كروسبوڤيدون، ستيرات المغنيسيوم، أوبادري OY-7300 أبيض، ايزوبربانول الكحول، اسيتون، ماء نقي، أكسيد الحديد الأصفر (<strong>كريسكول</strong><strong><sup>&reg;</sup></strong> 5 ملغم)، أكسيد الحديد الأحمر (<strong>كريسكول</strong><strong><sup>&reg;</sup></strong> 10ملغم و 20 ملغم).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف</strong><strong> </strong><strong>تبدو</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>و</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>العلبة</strong></p><p dir="RTL"><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> 5 </strong><strong>ملغم</strong><strong>: </strong>أقراص مغلفة دائرية الشكل، محدبة الوجهين ذات لون أصفر فاتح، محفور على أحد الأوجه H51، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> 10 </strong><strong>ملغم</strong><strong>: </strong>أقراص مغلفة دائرية الشكل، محدبة الوجهين ذات لون وردي فاتح، محفور على أحد الأوجه H53، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>كريسكول</strong><strong><sup>&reg;</sup></strong><strong> 20 </strong><strong>ملغم</strong><strong>: </strong>أقراص مغلفة دائرية الشكل، محدبة الوجهين ذات لون وردي فاتح، محفور على أحد الأوجه H55، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 قرص مغلف (10 أقراص/شريط، 3 أشرطة/عبوة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية- المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 - جدة 22429</p><p dir="RTL">بريد الكتروني: info@medcitypharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2024 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Creschol® 5 mg Film Coated Tablets. Creschol® 10 mg Film Coated Tablets. Creschol® 20 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Creschol® 5 mg: Each film coated tablet contains rosuvastatin Calcium equivalent to rosuvastatin 5 mg.
Creschol® 10 mg: Each film coated tablet contains rosuvastatin Calcium equivalent to rosuvastatin 10 mg.
Creschol® 20 mg: Each film coated tablet contains rosuvastatin Calcium equivalent to rosuvastatin 20 mg.

For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets.

Creschol® 5mg: Pale yellow, round biconvex film-coated tablets engraved with H51 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use. Creschol® 10mg: Light pink, round biconvex film-coated tablets engraved with H53 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use. Creschol® 20mg: Light pink, round biconvex film-coated tablets engraved with H55 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp; </strong><strong>Treatment of hypercholesterolaemia</strong></p><p>Adults, adolescents and children aged 6 years or older with primaryhypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p>Prevention of Cardiovascular Events</p><p>Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.</p><p><strong>Creschol<sup>&reg;</sup></strong><strong> </strong>may be given at any time of day, with or without food.</p><p>Treatment of hypercholesterolaemia</p><p>The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose</p><p>&nbsp;</p><p>level can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see section 4.4). Specialist supervision is recommended when the 40 mg dose is initiated.</p><p>Prevention of cardiovascular events</p><p>In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see section 5.1).</p><p>Paediatric population</p><p>Paediatric use should only be carried out by specialists.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V) Heterozygous familial hypercholesterolaemia</p><p>In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.</p><p>-&nbsp; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</p><p>-&nbsp; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</p><p>Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Homozygous familial hypercholesterolaemia</p><p>In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.</p><p>A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p>There is limited experience with doses other than 20 mg in this population. The 40 mg rosuvastatin tablet is not suitable for use in paediatric patients.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children younger than 6 years</p><p>The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, <strong>Creschol<sup>&reg;</sup> </strong>is not recommended for use in children younger than 6 years.</p><p>Use in the elderly</p><p>A start dose of 5 mg is recommended in patients &gt;70 years (see section 4.4). No other dose adjustment is necessary in relation to age.</p><p>Dosage in patients with renal insufficiency</p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of <strong>Creschol<sup>&reg;</sup> </strong>in patients with severe renal impairment is contraindicated for all doses (see sections 4.3 and 5.2).</p><p>&nbsp;</p><p>Dosage in patients with hepatic impairment</p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal function should be considered (see section 4.4). There is no experience in subjects with Child-Pugh scores above 9. <strong>Creschol<sup>&reg;</sup> </strong>is contraindicated in patients with active liver disease (see section 4.3).</p><p>Race</p><p>Increased systemic exposure has been seen in Asian subjects (see sections 4.3, 4.4 and 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p>Genetic polymorphisms</p><p>Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of <strong>Creschol<sup>&reg;</sup> </strong>is recommended.</p><p>Dosage in patients with pre-disposing factors to myopathy</p><p>The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see section 4.4).</p><p>The 40 mg dose is contraindicated in some of these patients (see section 4.3).</p><p>Concomitant therapy</p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when <strong>Creschol<sup>&reg;</sup> </strong>is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir and/or tipranavir; see sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing <strong>Creschol<sup>&reg;</sup></strong><strong> </strong>therapy. In situations where co-administration of these medicinal products with <strong>Creschol<sup>&reg;</sup> </strong>is unavoidable, the benefit and the risk of concurrent treatment and <strong>Creschol<sup>&reg;</sup></strong><strong> </strong>dosing adjustments should be carefully considered (see section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Creschol® is contraindicated:
•	In patients with hypersensitivity to rosuvastatin or to any of the excipients.
•	In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 times the upper limit of normal (ULN).
•	In patients with severe renal impairment (creatinine clearance <30 ml/min).
•	In patients with myopathy.
•	In patients receiving concomitant combination of sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
•	In patients receiving concomitant ciclosporin.
•	During pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.
The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:
•	Moderate renal impairment (creatinine clearance < 60 ml/min).
•	Hypothyroidism.
•	Personal or family history of hereditary muscular disorders.
 
•	Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate.
•	Alcohol abuse.
•	Situations where an increase in plasma levels may occur.
•	Asian patients.
•	Concomitant use of fibrates. (See sections 4.4, 4.5 and 5.2)


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Renal Effects</p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p>Skeletal Muscle Effects</p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in <strong>Creschol<sup>&reg;</sup> </strong>-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see section 4.5) and caution should be exercised with their combined use. As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with <strong>Creschol<sup>&reg;</sup> </strong>in post-marketing use is higher at the 40 mg dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Creatine Kinase Measurement</p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before Treatment</p><p><strong>Creschol<sup>&reg;</sup></strong>, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypothyroidism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personal or family history of hereditary muscular disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol abuse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age &gt;70 years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Situations where an increase in plasma levels may occur (see sections 4.2, 4.5 and 5.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant use of fibrates.</p><p>In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whilst on Treatment</p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be</p><p>&nbsp;</p><p>measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le;5xULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing <strong>Creschol<sup>&reg;</sup> </strong>or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring.</p><p>Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>In clinical trials, there was no evidence of increased skeletal muscle effects in the small number of patients dosed with <strong>Creschol<sup>&reg;</sup> </strong>and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG- CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG- CoA reductase inhibitors. Therefore, the combination of <strong>Creschol<sup>&reg;</sup> </strong>and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of <strong>Creschol<sup>&reg;</sup> </strong>with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.5 and 4.8).</p><p><strong>Creschol<sup>&reg;</sup></strong><strong> </strong>must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re- introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of <strong>Creschol<sup>&reg;</sup> </strong>and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p><strong>Creschol<sup>&reg;</sup></strong><strong> </strong>must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re- introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of <strong>Creschol<sup>&reg;</sup> </strong>and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p><strong>Creschol<sup>&reg;</sup> </strong>should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p>Severe Cutaneous Adverse Reactions</p><p>Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life- threatening or fatal, have been reported with rosuvastatin (see section 4.8). At the time of</p><p>&nbsp;</p><p>prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appear, <strong>Creschol<sup>&reg;</sup> </strong>should be discontinued immediately and an alternative treatment should be considered.</p><p>If the patient has developed a serious reaction such as SJS or DRESS with the use of</p><p><strong>Creschol<sup>&reg;</sup>, </strong>treatment with <strong>Creschol<sup>&reg;</sup> </strong>must not be restarted in this patient at any time.</p><p>Liver Effects</p><p>As with other HMG-CoA reductase inhibitors, <strong>Creschol<sup>&reg;</sup> </strong>should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p>It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. <strong>Creschol<sup>&reg;</sup> </strong>should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose.</p><p>In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with <strong>Creschol<sup>&reg;</sup></strong>.</p><p>Race</p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see sections 4.2, 4.3 and 5.2).</p><p>Protease Inhibitors</p><p>Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of <strong>Creschol<sup>&reg;</sup> </strong>in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating <strong>Creschol<sup>&reg;</sup> </strong>doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of <strong>Creschol<sup>&reg;</sup> </strong>is adjusted. (See sections 4.2 and 4.5).</p><p>Lactose Intolerance</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Interstitial Lung Disease</p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long-term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>Diabetes Mellitus</p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l. <strong>Paediatric Population</strong></p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years</p><p>&nbsp;</p><p>of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 5.1).</p><p>In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Effect of co-administered medicinal products on rosuvastatin</p><p><strong>Transporter protein inhibitors</strong>: Rosuvastatin is a substrate for certain transporter</p><p>proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of <strong>Creschol<sup>&reg;</sup> </strong>with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see sections 4.2, 4.4 and 4.5 Table 1).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ciclosporin</strong>: During concomitant treatment with <strong>Creschol<sup>&reg;</sup> </strong>and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). <strong>Creschol<sup>&reg;</sup> </strong>is contraindicated in patients receiving concomitant ciclosporin (see section 4.3). Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Protease inhibitors</strong>: Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir/100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC&nbsp;&nbsp; and Cmax respectively. The concomitant use of <strong>Creschol<sup>&reg;</sup> </strong>and some protease inhibitor combinations may be considered after careful consideration of <strong>Creschol<sup>&reg;</sup> </strong>dose adjustments based on the expected increase in rosuvastatin exposure (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><strong>Gemfibrozil and other lipid-lowering products</strong>: Concomitant use of rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin Cmax and AUC (see section 4.4).</p><p>Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1 g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG- CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections</p><p>4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p><strong>Ezetimibe: </strong>Concomitant use of 10 mg <strong>Creschol<sup>&reg;</sup> </strong>and 10 mg ezetimibe resulted in a 1.2- fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between <strong>Creschol<sup>&reg;</sup> </strong>and ezetimibe cannot be ruled out (see section 4.4).</p><p><strong>Antacid: </strong>The simultaneous dosing of <strong>Creschol<sup>&reg;</sup> </strong>with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after <strong>Creschol<sup>&reg;</sup>. </strong>The clinical relevance of this interaction has not been studied.</p><p>&nbsp;</p><p><strong>Erythromycin: </strong>Concomitant use of <strong>Creschol<sup>&reg;</sup> </strong>and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in Cmax of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p><strong>Ticagrelor: </strong>Ticagrelor might affect renal excretion of rosuvastatin, increasing the risk for rosuvastatin accumulation. Although the exact mechanism is not known, in some cases, concomitant use of ticagrelor and rosuvastatin led to renal function decrease, increased CPK level and rhabdomyolysis.</p><p><strong>Cytochrome P450 enzymes: </strong>Results from in vitro and in vivo studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1): </strong>When it is necessary to co-administer <strong>Creschol<sup>&reg;</sup> </strong>with other medicinal products known to increase exposure to rosuvastatin, doses of <strong>Creschol<sup>&reg;</sup> </strong>should be adjusted. Start with a 5 mg once daily dose of <strong>Creschol<sup>&reg;</sup> </strong>if the expected increase in exposure (AUC) is approximately 2- fold or higher. The maximum daily dose of <strong>Creschol<sup>&reg;</sup> </strong>should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of <strong>Creschol<sup>&reg;</sup> </strong>taken without interacting medicinal products, for example a 20 mg dose of <strong>Creschol<sup>&reg;</sup> </strong>with gemfibrozil (1.9-fold increase), and a 10 mg dose of <strong>Creschol<sup>&reg;</sup> </strong>with combination ritonavir/atazanavir (3.1-fold increase).</p><p>If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose need not be decreased but caution should be taken if increasing the <strong>Creschol<sup>&reg;</sup> </strong>dose above 20mg.</p><p>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</p><p><strong>2-fold or greater than 2-fold increase in AUC of rosuvastatin</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</strong></p><p><strong>rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days</p></td><td style="vertical-align:top"><p>10mg single dose</p></td><td style="vertical-align:top"><p>7.4 -fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darolutamide 600 mg BID, 5 days</p></td><td style="vertical-align:top"><p>5mg, single dose</p></td><td style="vertical-align:top"><p>5.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Regorafenib 160 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>3.8-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD,</p><p>8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Velpatasvir 100 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.7-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ombitasvir 25 mg/paritaprevir 150 mg/ Ritonavir 100 mg OD/ dasabuvir 400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>2.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Teriflunomide</p></td><td style="vertical-align:top"><p>Not Available</p></td><td style="vertical-align:top"><p>2.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Grazoprevir 200 mg/elbasvir 50 mg OD,</p><p>11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.3-fold &uarr;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Glecaprevir 400 mg/pibrentasvir 120 mg</p><p>OD, 7 days</p></td><td style="vertical-align:top"><p>5 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID,</p><p>17 days</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Fostamatinib 100 mg twice daily</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2.0-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Febuxostat 120 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Less than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</strong></p><p><strong>rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 600 mg/ritonavir 100 mg BID,</p><p>7 days</p></td><td style="vertical-align:top"><p>10 mg OD, 7 days</p></td><td style="vertical-align:top"><p>1.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID,</p><p>11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>**1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>**1.2-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Decrease in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</strong></p><p><strong>rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr></tbody></table><p>*Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone.</p><p>Increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;.</p><p>**Several interaction studies have been performed at different <strong>Creschol<sup>&reg;</sup> </strong>dosages, the table shows the most significant ratio</p><p>AUC = area under curve; OD = once daily; BID = twice daily; TID = three times daily; QID</p><p>= four times daily</p><p>The following medical product/combinations did not have a clinically significant effect on the AUC ratio of rosuvastatin at coadministration:</p><p>Aleglitazar 0.3 mg 7 days dosing; Fenofibrate 67 mg 7 days TID dosing; Fluconazole 200mg 11 days OD dosing; Fosamprenavir 700 mg/ritonavir 100 mg 8 days BID dosing; Ketoconazole 200 mg 7 days BID dosing; Rifampin 450 mg 7 days OD dosing; Silymarin 140 mg 5 days TID dosing.</p><p>Effect of rosuvastatin on co-administered medicinal products</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vitamin</strong><strong> </strong><strong>K</strong><strong> </strong><strong>antagonists: </strong>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of <strong>Creschol<sup>&reg;</sup> </strong>in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or</p><p>&nbsp;</p><p>down-titration of <strong>Creschol<sup>&reg;</sup> </strong>may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Oral contraceptive/hormone replacement therapy (HRT): </strong>Concomitant use of <strong>Creschol<sup>&reg;</sup> </strong>and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant <strong>Creschol<sup>&reg;</sup> </strong>and HRT, therefore, a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p>Other medicinal products:</p><p><strong>Digoxin: </strong>Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p><strong>Fusidic Acid: </strong>Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy, including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, <strong>Creschol<sup>&reg;</sup> </strong>treatment should be discontinued throughout the duration of the fusidic acid treatment. Also see section 4.4. <strong>Paediatric population</strong>: Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Creschol<sup>&reg;</sup></strong><strong> </strong>is contraindicated in pregnancy and lactation.</p><p>Women of child bearing potential should use appropriate contraceptive measures.</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see section 4.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of rosuvastatin on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, <strong>Creschol<sup>&reg;</sup> </strong>is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with <strong>Creschol<sup>&reg;</sup></strong><strong> </strong>are generally mild and transient. In controlled clinical trials, less than 4% of <strong>Creschol<sup>&reg;</sup></strong>-treated patients were withdrawn due to adverse reactions.</p><p>Tabulated list of adverse reactions</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>&nbsp;</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to</p><p>&lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data). <strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyneuropathy Memory loss</p></td><td style="vertical-align:top"><p>Peripheral neuropathy Sleep disturbances (including insomnia and nightmares)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastro- intestinal disorders</p></td><td style="vertical-align:top"><p>Constipation Nausea Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased hepatic transaminases</p></td><td style="vertical-align:top"><p>Jaundice Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus Rash Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens- Johnson syndrome Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Musculo- skeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myopathy (including myositis) Rhabdomyolysis Lupus-like syndrome Muscle rupture</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Tendon disorders, sometimes complicated by</p><p>rupture Immune- mediated necrotising myopathy</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1</sup> Frequency will depend on the presence or absence of risk factors (fasting blood glucose</p><p>&ge; 5.6 mmol/L, BMI &gt;30 kg/m2, raised triglycerides, history of hypertension).</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p><strong>Renal effects: </strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with <strong>Creschol<sup>&reg;</sup> </strong>and clinical trial data show that the occurrence is low.</p><p><strong>Skeletal muscle effects: </strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in <strong>Creschol<sup>&reg;</sup></strong>-treated patients with all doses and in particular with doses &gt; 20 mg. A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see section 4.4).</p><p><strong>Liver effects: </strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>&nbsp;</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><strong>Paediatric population</strong>: Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52- week clinical trial of children and adolescents compared to adults (see section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp; Other GCC States:</p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>HMG-CoA reductase inhibitors, <strong>ATC code: </strong>C10A A07</p><p>Mechanism of action</p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate- limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p>Pharmacodynamic effects</p><p><strong>Creschol<sup>&reg;</sup> </strong>reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, non-HDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). <strong>Creschol<sup>&reg;</sup> </strong>also lowers the LDL-C/HDL-C, total C/HDL-C and non-HDL-C/HDL-C and the ApoB/ApoA-I ratios.</p><p>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p></td><td style="vertical-align:top"><p><strong>nonHDL-C</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p></td><td style="vertical-align:top"><p><strong>ApoA-I</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p>Clinical efficacy and safety</p><p><strong>Creschol<sup>&reg;</sup> </strong>is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex or age and in special populations such as diabetics or patients with familial hypercholesterolaemia.</p><p>From pooled phase III data, <strong>Creschol<sup>&reg;</sup> </strong>has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/L) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/L).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. Thirty-three percent (33%) of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/L).</p><p>In a force-titration, open label trial, 42 patients (including 8 paediatric patients) with homozygous familial hypercholesterolaemia were evaluated for their response to rosuvastatin 20 &ndash; 40 mg. In the overall population, the mean LDL-C reduction was 22%. In clinical studies with a limited number of patients, rosuvastatin has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/L (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non- significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of rosuvastatin 40 mg. The 40 mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient- years was 8.8. Total mortality was unchanged in this high-risk group (p=0.193). In a post- hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline</p><p>&nbsp;</p><p>SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high-risk group (p=0.076).</p><p>In the JUPITER trial, there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).</p><p>Paediatric population</p><p>In a double-blind, randomised, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10 to 17 years of age (Tanner stage II-V, females at least 1-year post-menarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10 to 13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/L.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily. After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, Month 24: 124</p><p>mg/dL) and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non- HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL C/HDL-C, ApoB, ApoB/ApoA-1.</p><p>These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4).</p><p>Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multi-centre, cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolaemia. The study</p><p>&nbsp;</p><p>included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12- week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study.</p><p>A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), non-HDL-C (22.9%, p=0.003) and ApoB (17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, non-HDL-C/HDL-C and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy. One patient had a further reduction in LDL-C (8.0%), Total-C (6.7%) and non-HDL-C (7.4%) following 6 weeks of treatment with 40 mg after up-titration.</p><p>During an extended open-label treatment in 9 of these patients with 20 mg rosuvastatin for up to 90 weeks, the LDL-C reduction was maintained in the range of -12.1% to -21.3%. In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force-titration open label study with homozygous familial hypercholesterolaemia (see above), the percent reduction in LDL-C (21.0%), Total-C (19.2%) and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolaemia.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption: </strong>Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p><strong>Distribution: </strong>Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p><strong>Metabolism: </strong>Rosuvastatin undergoes limited metabolism (approximately 10%). In vitro metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p><strong>Excretion: </strong>Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic</p><p>&nbsp;</p><p>uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p><strong>Linearity: </strong>Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p>Special populations:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Age and sex: </strong>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolemia appears to be similar to or lower than that in adult patients with dyslipidaemia (see &ldquo;Paediatric population&rdquo; below).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Race: </strong>Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and Cmax in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal insufficiency: </strong>In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl</p><p>&lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic insufficiency: </strong>In a study with subjects with varying degrees of hepatic impairment, there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child- Pugh scores above 9.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Genetic polymorphisms: </strong>Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of rosuvastatin is recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Paediatric population: </strong>Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10 to 17 or 6 to 17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent</p><p>&nbsp;</p><p>with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tribasic calcium phosphate anhydrous, microcrystalline cellulose, lactose monohydrate, spray dried lactose monohydrate, crospovidone, magnesium stearate, opadry OY-7300 white, isoprpranolol alcohol, acetone, purified water, yellow Iron oxide (<strong>Creschol<sup>&reg;</sup> </strong>5mg), red Iron oxide (<strong>Creschol<sup>&reg;</sup> </strong>10mg and 20mg)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Creschol<sup>&reg;</sup> 5mg: </strong>Pale yellow, round biconvex film-coated tablets engraved with H51 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use. <strong>Creschol<sup>&reg;</sup> 10mg: </strong>Light pink, round biconvex film-coated tablets engraved with H53 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use. <strong>Creschol<sup>&reg;</sup> 20mg: </strong>Light pink, round biconvex film-coated tablets engraved with H55 on one side and plain on the other side, presented in Alu/Alu blisters, intended for oral use. <strong>Pack size: </strong>30 Film Coated Tablets (10 tablets/blister, 3 blisters/Pack).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma – KSA. Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551 E-mail: MD.admin@Axantia.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>